

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 1, 2007

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

22-0760120

(Commission File Number)

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

07417-1880

(Address of Principal Executive Offices)

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On November 1, 2007, Becton, Dickinson and Company ("BD") issued a press release announcing its financial results for its fourth fiscal quarter and fiscal year ending September 30, 2007. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (GAAP), as follows:

- Revenues. We present revenue growth rates at constant foreign exchange rates. We believe that presenting revenue growth rates at constant foreign exchange rates allows investors to view the underlying operating results of BD and of its segments without the impact of fluctuations in foreign currency exchange rates, thereby facilitating comparisons to prior periods.
- Selling and Administrative Expense. We present selling and administrative expense, both alone and as a percentage of revenues, for fiscal year 2006 after excluding the impact of insurance settlements occurring during the fiscal year. These settlements caused reported selling and administrative expense to be lower than it otherwise would have been for the fiscal year, although these settlements are not considered part of ordinary operations by management. Accordingly, we believe that measures of selling and administrative expense that are adjusted for the effects of these settlements are more indicative of BD's underlying performance and assist investors in comparing BD's selling and administrative expense for the period to other periods.
- Operating Income. We present BD's operating income, both alone and as a percentage of revenues, for fiscal year 2007 after excluding the impact of the in-process research and development ("R&D") charges relating to our acquisition of Plasso Technology, Ltd ("Plasso") and our acquisition of TriPath Imaging, Inc. ("TriPath"). We also present these measures for fiscal year 2006 after excluding the impact of the previously mentioned insurance settlements and the impact of the in-process R&D charge relating to the acquisition of GeneOhm Sciences, Inc. ("GeneOhm"). These items affected reported operating income for the period in which they occurred, but are not considered by management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of operating income are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative operating performance for the period presented.
- Income Taxes/Effective Tax Rate. We present the effective tax rate for fiscal year 2007 after excluding the impact of the in-process R&D charges relating to our acquisitions of Plasso and TriPath, respectively. These items, which are not considered part of ordinary operations by management and are not tax deductible, caused our effective tax rate for the fiscal year to be higher than it otherwise would have been.

We also present income taxes and effective tax rate for fiscal year 2006 after excluding the impact of the previously mentioned insurance settlements. These settlements caused our reported income tax expense and effective tax rate for the fiscal year to be higher than they otherwise would have been, although these settlements are not considered part of ordinary operations by management. The adjusted effective tax rate we present for fiscal year 2006 also excludes the impact of the in-process R&D charge relating to our acquisition of GeneOhm. This item, which is not tax deductible, caused our effective tax rate for the fiscal year to be higher than it otherwise would have been, although this item is not considered part of ordinary operations by management.

Management believes that these adjusted measures of income taxes and effective tax rate are more indicative of BD's underlying results, and also allow investors to better understand BD's comparative income tax expense and tax rate for the fiscal year.

- Income from Continuing Operations. We present BD's income from continuing operations, both alone and as a percentage of revenues, for fiscal year 2007 after excluding the impact of the in-process R&D charges relating to the Plasso and TriPath acquisitions, respectively. We also present BD's income from continuing operations, both alone and as a percentage of revenues, for fiscal year 2006 after excluding the impact of the previously mentioned insurance settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported income from continuing operations for the period in which they occurred, but are not considered by
-

management to be part of ordinary operations. Accordingly, management believes that these adjusted measures of income from continuing operations are more indicative of BD's underlying performance, and also allow investors to better understand BD's comparative income from continuing operations for the period presented.

- **Earnings Per Share.** We present earnings per share from continuing operations for fiscal year 2007 after excluding the impact of the in-process R&D charges relating to the TriPath and Plaso acquisitions, respectively. These charges caused reported earnings per share for the fiscal year to be lower than it otherwise would have been, although these charges are not considered by management to be part of ordinary operations. We believe that a measure of earnings per share that is adjusted for the impact of these charges is more indicative of BD's underlying performance and also allows investors to more easily compare BD's results for the fiscal year to other periods.

We also present earnings per share from continuing operations for the 2006 fiscal year after excluding the impact of the previously mentioned insurance settlements and the in-process R&D charge relating to the GeneOhm acquisition. These items affected reported earnings per share for the fiscal year, but are not considered by management to be part of ordinary operations. Accordingly, management believes that this adjusted measure of earnings per share is more indicative of BD's underlying performance, and also allows investors to better understand BD's comparative performance for the fiscal year.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits. — Exhibit 99.1 Press release dated November 1, 2007, which is furnished pursuant to Item 2.02.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Paranicas
Dean J. Paranicas
Vice President, Corporate
Secretary and Public Policy

Date: November 1, 2007

INDEX TO EXHIBITS

**Exhibit
Number**

Description of Exhibits

99.1

Press release dated November 1, 2007, which is furnished pursuant to Item 2.02.

News Release



Contact:

Patricia A. Spinella, Investor Relations – 201-847-5453
Colleen T. White, Corporate Communications – 201-847-5369

BD ANNOUNCES RESULTS FOR FOURTH FISCAL QUARTER AND FULL YEAR

- Reports record revenues for the quarter and year
- Fourth-quarter earnings per share from continuing operations increased 15% to 98 cents
- Full-year earnings per share from continuing operations, excluding specified items, increased 15% to \$3.84
- Expects full fiscal year 2008 earnings per share from continuing operations, excluding specified items, to increase 10%-12%

Franklin Lakes, NJ (November 1, 2007) – BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.651 billion for the fourth fiscal quarter ended September 30, 2007, representing an increase of 13 percent over the prior year period. This quarter's growth rate reflects the favorable impact on all segments from foreign currency translation, which overall is estimated to account for 3 percentage points of the increase in quarterly revenues.

For the full fiscal year ended September 30, 2007, BD reported record revenues of \$6.360 billion, representing an increase of 11 percent over the prior year, which reflects an overall estimated 3 percent favorable impact from foreign currency translation that affected all segments.

“We are pleased with our solid finish to another successful year during which BD exceeded its financial and operating goals,” said Edward J. Ludwig, Chairman, President and Chief Executive Officer. “Our performance was strong across all three segments. We continue to invest in innovation while delivering double-digit earnings growth. Strong cash flow driven by operating margin expansion enables us to return value to shareholders through dividend increases and share repurchases. We are enthusiastic about our outlook for fiscal 2008.”

Fourth Quarter Earnings and Analysis of Full Fiscal Year 2007 and 2006 Earnings

Reported diluted earnings per share from continuing operations of 98 cents for the fourth quarter increased by 15 percent over diluted earnings per share from continuing operations of 85 cents for the fourth fiscal quarter of 2006.

For the twelve-month period ending September 30, 2007, reported diluted earnings per share were \$3.36. The following analysis (Table 1) of diluted earnings per share from continuing operations for the twelve-month periods ended September 30, 2007 and 2006 identifies specified items that affect the comparability of results between periods. As illustrated, diluted earnings per share from continuing operations, excluding specified items, of \$3.84 for fiscal 2007 increased by 15 percent over diluted earnings per share from continuing operations, excluding specified items, of \$3.34 for fiscal 2006.

	Twelve Months Ended September 30,		
	FY2007	FY2006	% Change
Diluted EPS from Continuing Operations:	\$ 3.36	\$ 3.18	6%
<u>Specified Items:</u>			
In-Process Research and Development Charge ⁽¹⁾	0.48	0.21	
Insurance Settlement ⁽²⁾	-	(0.04)	
Rounding	-	(0.01)	
	<u>0.48</u>	<u>0.16</u>	
Diluted EPS from Continuing Operations Excluding Specified Items:	<u>\$ 3.84</u>	<u>\$ 3.34</u>	<u>15%</u>

(1) Represents the effect on diluted earnings per share from continuing operations of the in-process research and development ("IPR&D") charges recorded in fiscal 2007 primarily related to the TriPath acquisition, and in fiscal 2006 related to the GeneOhm acquisition.

(2) Represents the effect on diluted earnings per share from continuing operations in fiscal 2006 related to proceeds received from insurance settlements associated with the Company's previously owned latex glove business.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$868 million, representing an increase of 11 percent from the prior year period. For the full fiscal year ended September 30, 2007, the BD Medical segment reported 10 percent revenue growth to \$3.421 billion. Strong sales in the Pharmaceutical Systems unit continued to significantly contribute to the growth of the segment.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$498 million, representing an increase of 16 percent from the prior year's quarter. This growth includes \$29 million of revenues from TriPath, a maker of innovative solutions to improve the clinical management of cancer, which was acquired at the end of the first quarter of fiscal 2007. For the full fiscal year ended September 30, 2007, the BD Diagnostics segment reported revenue growth of 11 percent to \$1.905 billion, which includes \$88 million of revenues from TriPath.

In the BD Biosciences segment, worldwide revenues for the quarter were \$285 million, representing an increase of 14 percent from the prior year period. Sales of flow cytometry and bioimaging instruments, flow cytometry reagents, and advanced bioprocessing products contributed to growth. For the full fiscal year ended September 30, 2007, the BD Biosciences segment reported 13 percent revenue growth to \$1.034 billion, resulting from continued strong sales of those same products.

Geographic Results

Fourth quarter revenues in the U.S. were \$790 million, representing an increase of 12 percent over the prior year period. Revenues outside the U.S. were \$861 million, representing an increase of 13 percent over the prior year period, and reflected an estimated 5 percent favorable impact from foreign currency translation.

For the full fiscal year ended September 30, 2007, revenues in the U.S. were \$3.033 billion, representing an increase of 11 percent over the prior year period. Revenues outside of the U.S. were \$3.327 billion, representing an increase of 11 percent over the prior year period, and reflected an estimated 5 percent favorable impact from foreign currency translation.

Fiscal 2008 Outlook for Full Year

The Company estimates that diluted earnings per share from continuing operations for the full fiscal year 2008 will increase approximately 10 to 12 percent over diluted earnings per share from continuing operations, excluding specified items, of \$3.84 for the fiscal year 2007.

Conference Call Information

A conference call regarding BD's fourth fiscal quarter and full year results and its expectations for fiscal year 2008 will be broadcast live on BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Thursday, November 1, 2007. The conference call will be available for replay through the close of business on November 8, 2007 on BD's website, www.bd.com/investors, or at 1-800-475-6701 (domestic) and 1-320-365-3844 (international), access code 889224.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2008 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product

introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	Three Months Ended September 30,		
	2007	2006	% Change
REVENUES	\$ 1,651,101	\$ 1,462,616	12.9
Cost of products sold	807,377	709,038	13.9
Selling and administrative	399,525	378,252	5.6
Research and development	100,430	82,399	21.9
TOTAL OPERATING COSTS AND EXPENSES	1,307,332	1,169,689	11.8
OPERATING INCOME	343,769	292,927	17.4
Interest expense	(10,268)	(14,056)	(26.9)
Interest income	9,083	15,488	(41.4)
Other expense, net	(4,334)	(4,763)	(9.0)
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	338,250	289,596	16.8
Income tax provision	89,142	72,716	22.6
INCOME FROM CONTINUING OPERATIONS	249,108	216,880	14.9
INCOME/(LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION/(BENEFIT) OF \$1,176 AND \$(20,695), RESPECTIVELY	1,923	(42,901)	NM
NET INCOME	\$ 251,031	\$ 173,979	44.3
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.02	\$ 0.88	15.9
Income/(loss) from discontinued operations	\$ 0.01	\$ (0.17)	NM
Net income	\$ 1.03	\$ 0.71	45.1
Diluted:			
Income from continuing operations	\$ 0.98	\$ 0.85	15.3
Income/(loss) from discontinued operations	\$ 0.01	\$ (0.17)	NM
Net income	\$ 0.99	\$ 0.68	45.6
AVERAGE SHARES OUTSTANDING			
Basic	243,841	245,522	
Diluted	253,009	254,843	

NM - Not Meaningful

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

	Twelve Months Ended September 30,		
	2007	2006	% Change
REVENUES	\$ 6,359,708	\$ 5,738,017	10.8
Cost of products sold	3,071,921	2,793,265	10.0
Selling and administrative	1,602,404	1,448,166	10.7
Research and development	360,050	301,872	19.3
Acquired in-process research and development	122,133	53,300	NM
TOTAL OPERATING COSTS AND EXPENSES	5,156,508	4,596,603	12.2
OPERATING INCOME	1,203,200	1,141,414	5.4
Interest expense	(46,420)	(66,046)	(29.7)
Interest income	46,221	59,296	(22.1)
Other expense, net	944	(8,762)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	1,203,945	1,125,902	6.9
Income tax provision	347,778	310,792	11.9
INCOME FROM CONTINUING OPERATIONS	856,167	815,110	5.0
INCOME (LOSS) FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION/(BENEFIT) OF \$15,242 AND \$(32,823), RESPECTIVELY	25,085	(62,830)	NM
NET INCOME	\$ 881,252	\$ 752,280	17.1
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 3.50	\$ 3.30	6.1
Income (loss) from discontinued operations	\$ 0.10	\$ (0.25)	NM
Net income (1)	\$ 3.60	\$ 3.04	18.4
Diluted:			
Income from continuing operations	\$ 3.36	\$ 3.18	5.7
Income (loss) from discontinued operations	\$ 0.10	\$ (0.24)	NM
Net income (1)	\$ 3.46	\$ 2.93	18.1
AVERAGE SHARES OUTSTANDING			
Basic	244,929	247,067	
Diluted	254,810	256,554	

NM - Not Meaningful

(1) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL INFORMATION
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands, except per-share data)

	2007			
	As Reported	TriPath IPR&D(1)	Plasso IPR&D (1)	Excluding Items
Operating Income	\$ 1,203,200	\$ 114,739	\$ 7,394	\$ 1,325,333
as a % of revenues	18.9%			20.8%
Income taxes	347,778	-	-	347,778
effective tax rate	28.9%			26.2%
Income from continuing operations	856,167	114,739	7,394	978,300
as a % of revenues	13.5%			15.4%
<u>Diluted earnings per share</u>				
Income from continuing operations	\$ 3.36	\$ 0.45	\$ 0.03	\$ 3.84

(1) Represents the acquired in-process research and development charges of \$114,739 and \$7,394 related to the TriPath and Plasso acquisitions, respectively.

	2006			
	As Reported	Insurance Settlement (1)	GeneOhm IPR&D (2)	Excluding Items
Selling and administrative	\$ 1,448,166	\$ 17,000	\$ -	\$ 1,465,166
as a % of revenues	25.2%			25.5%
Operating Income	1,141,414	(17,000)	53,300	1,177,714
as a % of revenues	19.9%			20.5%
Income taxes	310,792	(6,460)	-	304,332
effective tax rate	27.6%			26.2%
Income from continuing operations	815,110	(10,540)	53,300	857,870
as a % of revenues	14.2%			15.0%
<u>Diluted earnings per share</u>				
Income from continuing operations (3)	\$ 3.18	\$ (0.04)	\$ 0.21	\$ 3.34

(1) Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business.

(2) Represents the acquired in-process research and development charge of \$53,300 related to the GeneOhm acquisition.

(3) Total per share amounts may not add due to rounding.

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Three Months Ended September 30,		
	2007	2006	% Change
<u>BD MEDICAL</u>			
United States	\$ 392,166	\$ 361,198	8.6
International	476,128	422,616	12.7
TOTAL	\$ 868,294	\$ 783,814	10.8
<u>BD DIAGNOSTICS</u>			
United States	\$ 272,743	\$ 232,343	17.4
International	225,206	196,523	14.6
TOTAL	\$ 497,949	\$ 428,866	16.1
<u>BD BIOSCIENCES</u>			
United States	\$ 125,367	\$ 110,319	13.6
International	159,491	139,617	14.2
TOTAL	\$ 284,858	\$ 249,936	14.0
<u>TOTAL REVENUES</u>			
United States	\$ 790,276	\$ 703,860	12.3
International	860,825	758,756	13.5
TOTAL	\$ 1,651,101	\$ 1,462,616	12.9

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Twelve Months Ended September 30,		
	2007	2006	% Change
<u>BD MEDICAL</u>			
United States	\$ 1,538,308	\$ 1,418,077	8.5
International	1,882,362	1,688,569	11.5
TOTAL	\$ 3,420,670	\$ 3,106,646	10.1
<u>BD DIAGNOSTICS</u>			
United States	\$ 1,054,388	\$ 919,071	14.7
International	850,717	796,019	6.9
TOTAL	\$ 1,905,105	\$ 1,715,090	11.1
<u>BD BIOSCIENCES</u>			
United States	\$ 440,309	\$ 402,196	9.5
International	593,624	514,085	15.5
TOTAL	\$ 1,033,933	\$ 916,281	12.8
<u>TOTAL REVENUES</u>			
United States	\$ 3,033,005	\$ 2,739,344	10.7
International	3,326,703	2,998,673	10.9
TOTAL	\$ 6,359,708	\$ 5,738,017	10.8

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY BUSINESS SEGMENTS AND UNITS
 Three Months Ended September 30,
 (Unaudited; Amounts in thousands)

	United States		
	2007	2006	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 243,427	\$ 231,932	5.0
Diabetes Care	98,384	90,789	8.4
Pharmaceutical Systems	44,376	32,856	35.1
Ophthalmic Systems	5,979	5,621	6.4
TOTAL	\$ 392,166	\$ 361,198	8.6
BD DIAGNOSTICS			
Preanalytical Systems	\$ 138,203	\$ 131,838	4.8
Diagnostic Systems	134,540	100,505	33.9
TOTAL	\$ 272,743	\$ 232,343	17.4
BD BIOSCIENCES			
Discovery Labware	\$ 40,234	\$ 37,377	7.6
Immunocytometry Systems	64,232	52,679	21.9
Pharmingen	20,901	20,263	3.1
TOTAL	\$ 125,367	\$ 110,319	13.6
TOTAL UNITED STATES	\$ 790,276	\$ 703,860	12.3

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

			International		
	2007	2006	Reported	% Change	
				FX Neutral	FX Impact
<u>BD MEDICAL</u>					
Medical Surgical Systems	\$ 233,366	\$ 215,951	8.1	2.0	6.1
Diabetes Care	82,851	75,337	10.0	4.5	5.5
Pharmaceutical Systems	149,023	121,886	22.3	15.9	6.4
Ophthalmic Systems	10,888	9,442	15.3	8.9	6.4
TOTAL	\$ 476,128	\$ 422,616	12.7	6.6	6.1
<u>BD DIAGNOSTICS</u>					
Preanalytical Systems	\$ 122,337	\$ 107,399	13.9	7.5	6.4
Diagnostic Systems	102,869	89,124	15.4	10.3	5.1
TOTAL	\$ 225,206	\$ 196,523	14.6	8.8	5.8
<u>BD BIOSCIENCES</u>					
Discovery Labware	\$ 32,976	\$ 30,601	7.8	3.1	4.7
Immunocytometry Systems	105,403	89,768	17.4	12.6	4.8
Pharmingen	21,112	19,248	9.7	4.6	5.1
TOTAL	\$ 159,491	\$ 139,617	14.2	9.4	4.8
TOTAL INTERNATIONAL	\$ 860,825	\$ 758,756	13.5	7.7	5.8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

			Total		
	2007	2006	Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 476,793	\$ 447,883	6.5	3.5	3.0
Diabetes Care	181,235	166,126	9.1	6.6	2.5
Pharmaceutical Systems	193,399	154,742	25.0	20.0	5.0
Ophthalmic Systems	16,867	15,063	12.0	7.9	4.1
TOTAL	\$ 868,294	783,814	10.8	7.5	3.3
BD DIAGNOSTICS					
Preanalytical Systems	\$ 260,540	\$ 239,237	8.9	6.0	2.9
Diagnostic Systems	237,409	189,629	25.2	22.8	2.4
TOTAL	\$ 497,949	428,866	16.1	13.4	2.7
BD BIOSCIENCES					
Discovery Labware	\$ 73,210	\$ 67,978	7.7	5.6	2.1
Immunocytometry Systems	169,635	142,447	19.1	16.0	3.1
Pharmingen	42,013	39,511	6.3	3.8	2.5
TOTAL	\$ 284,858	249,936	14.0	11.3	2.7
TOTAL REVENUES	\$ 1,651,101	\$ 1,462,616	12.9	9.9	3.0

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY BUSINESS SEGMENTS AND UNITS
 Twelve Months Ended September 30,
 (Unaudited; Amounts in thousands)

	United States		
	2007	2006	% Change
BD MEDICAL			
Medical Surgical Systems	\$ 954,971	\$ 904,371	5.6
Diabetes Care	378,639	363,298	4.2
Pharmaceutical Systems	180,337	127,896	41.0
Ophthalmic Systems	24,361	22,512	8.2
TOTAL	\$ 1,538,308	\$ 1,418,077	8.5
BD DIAGNOSTICS			
Preanalytical Systems	\$ 541,415	\$ 511,948	5.8
Diagnostic Systems	512,973	407,123	26.0
TOTAL	\$ 1,054,388	\$ 919,071	14.7
BD BIOSCIENCES			
Discovery Labware	\$ 149,939	\$ 138,205	8.5
Immunocytometry Systems	210,916	186,369	13.2
Pharmingen	79,454	77,622	2.4
TOTAL	\$ 440,309	\$ 402,196	9.5
TOTAL UNITED STATES	\$ 3,033,005	\$ 2,739,344	10.7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	International				
	2007	2006	Reported	% Change	
				FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 909,109	\$ 844,372	7.7	2.8	4.9
Diabetes Care	317,342	293,235	8.2	3.3	4.9
Pharmaceutical Systems	611,563	511,798	19.5	12.5	7.0
Ophthalmic Systems	44,348	39,164	13.2	6.7	6.5
TOTAL	\$ 1,882,362	\$ 1,688,569	11.5	5.9	5.6
BD DIAGNOSTICS					
Preanalytical Systems	\$ 465,276	\$ 415,811	11.9	6.2	5.7
Diagnostic Systems	385,441	380,208	1.4	(2.5)	3.9
TOTAL	\$ 850,717	\$ 796,019	6.9	2.0	4.9
BD BIOSCIENCES					
Discovery Labware	\$ 127,963	\$ 117,880	8.6	4.4	4.2
Immunocytometry Systems	377,485	316,478	19.3	14.2	5.1
Pharmingen	88,176	79,727	10.6	5.8	4.8
TOTAL	\$ 593,624	\$ 514,085	15.5	10.7	4.8
TOTAL INTERNATIONAL	\$ 3,326,703	\$ 2,998,673	10.9	5.7	5.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	Total				
	2007	2006	Reported	FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 1,864,080	\$ 1,748,743	6.6	4.2	2.4
Diabetes Care	695,981	656,533	6.0	3.8	2.2
Pharmaceutical Systems	791,900	639,694	23.8	18.2	5.6
Ophthalmic Systems	68,709	61,676	11.4	7.3	4.1
TOTAL	\$ 3,420,670	\$ 3,106,646	10.1	7.1	3.0
BD DIAGNOSTICS					
Preanalytical Systems	\$ 1,006,691	\$ 927,759	8.5	5.9	2.6
Diagnostic Systems	898,414	787,331	14.1	12.2	1.9
TOTAL	\$ 1,905,105	\$ 1,715,090	11.1	8.8	2.3
BD BIOSCIENCES					
Discovery Labware	\$ 277,902	\$ 256,085	8.5	6.6	1.9
Immunocytometry Systems	588,401	502,847	17.0	13.8	3.2
Pharmingen	167,630	157,349	6.5	4.1	2.4
TOTAL	\$ 1,033,933	\$ 916,281	12.8	10.1	2.7
TOTAL REVENUES	\$ 6,359,708	\$ 5,738,017	10.8	8.1	2.7